Is Semaglutide from Lumera Labs HPLC verified?

Yes. Every Semaglutide lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is Semaglutide sold for human use?

No. Semaglutide is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is Semaglutide shipped?

Semaglutide is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for Semaglutide?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

4.6 · 209 researcher reviews

GLP-1 · Metabolic Axis

Semaglutide

SKU LUM-SEMA-5 · C₁₈₇H₂₉₁N₄₅O₅₉ · 4113.58 g/mol · CAS 910463-68-2

A 31-residue GLP-1 receptor agonist with a fatty-acid side chain at Lys26 for albumin-mediated half-life extension. Lyophilized from acetate buffer; reconstitute with bacteriostatic water for in-vitro receptor assays.

Purity (HPLC): ≥ 99.41%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$110CAD / 10 mg vial

In stock · Lot 26-A031

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist used as a reference standard in metabolic and incretin-axis research. The C18 fatty diacid attached at Lys26 binds serum albumin reversibly, conferring a 165-hour effective half-life in mammalian models and reducing assay-to-assay drift in time-course studies.

Each vial is lyophilized from acetate-buffered solution at pH 4.0, sealed under nitrogen, and held at −20 °C through ship. Cold-chain insulation is maintained from our Kelowna facility to your bench.

Research applications

In-vitro GLP-1R potency assays, β-arrestin recruitment screens, comparative pharmacokinetics versus exenatide and liraglutide, and structural studies of receptor-bound conformations. Compatible with HEK293, CHO, and INS-1E cell lines.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Molecular formula	C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight	4113.58 g/mol
CAS number	910463-68-2
Sequence length	31 residues
Modification	γ-Glu-C18 diacid at Lys26

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot 26-A031: 99.41%)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot 26-A031

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

Method	Result
RP-HPLC at 220 nm	99.41% main peak
ESI-MS (positive)	4113.6 Da (theor. 4113.58)
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155.

Lau J et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58(18):7370–80.

Citing this material

Semaglutide reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-SEMA-5, Lot 26-A031.

Related · Metabolic axis

Often paired in studies.

View catalog →

GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →

Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →

Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →

Growth axis

AOD-9604

10 mg · ≥ 99.0%

$36 CADView →

Why Lumera

Janoshik Analytical HPLC ≥ 99.41% on this lot
LC-MS identity confirmed before release
LAL endotoxin below detection limit
Cold-chain shipped −20°C from Kelowna, BC

Background research

What the literature says about Semaglutide.

Mechanism

Semaglutide is a long-acting GLP-1 analog, classified within the incretin signaling pathway. Structurally it is a C20 fatty-diacid GLP-1R agonist. Semaglutide is a 31-residue analog of human glucagon-like peptide-1 (GLP-1) bearing a C18 diacid attachment via a γ-glutamyl spacer at Lys26. Lau et al. (2015) reported its discovery and characterized its sub-nanomolar GLP-1R potency and extended functional half-life. Marso et al. (2016) followed with the SUSTAIN-6 cardiovascular outcomes data.

In an in-vitro setting, Semaglutide interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.

Common research applications

In-vitro receptor-binding and dose-response screens against the incretin signaling target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Semaglutide's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.

Storage & handling

Semaglutide arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.

References

Lau J et al. J Med Chem. 2015;58(18):7370-80.
Marso SP et al. N Engl J Med. 2016;375(19):1834-44.
Knudsen LB. Front Endocrinol. 2019;10:155.

For laboratory research only. Semaglutide is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.